EUVIMEDOdkrijte EUVIMED
Open access · CC BY-NC-ND 4.0

Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor

Maia Gill, Marianna Leung iD, Cindy Y Luo, Catherine Cheung iD, Arielle Beauchesne, Doris Chang, James Lan, Olwyn Johnston iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.15013 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Maia Gill and 7 co-authors. Institution: University of British Columbia, Division of Nephrology, Kidney Transplant program, Vancouver, Canada. Major MEDLINE topics: Polycythemia, Kidney Transplantation, Thrombosis, Diabetes Mellitus, Type 2. Cited 2 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Introduction

The safety and efficacy of sodium glucose cotransport‐2 inhibitors (SGLT2i) in kidney transplant recipients remains uncertain. Transplant recipients may be at risk of thrombosis because of post‐transplant erythrocytosis and SGLT2i are associated with an increase in hematocrit.

Methods

We determined SGLT2i use, the change in hematocrit and incidence of thrombotic events in kidney transplant recipients in 1700 prevalent patients in our center.

Results

Among the 42 patients treated with SGLT2i, the mean pre‐transplant hematocrit was 31%, and none of the patients had a hematocrit ≥50%. The mean percent change in hematocrit measured at an average of 53 days after initiation of an SGLT2i was 11% and four patients (10%) had a hematocrit ≥ 50%. The mean hematocrit measured 3 months after treatment was 42% and two patients (5%) had a hematocrit ≥50%. One patient had a cerebellar stroke 14 months post‐SGLT2i initiation when the hemoglobin was 173 grams/liter, and the hematocrit was 52%.

Conclusions

All patients had a sustained increase in hematocrit 3 months after SGLT2i treatment. Hematocrit ≥50% occurred in 10%, and one patient had a thrombotic event that may or may not have been related to an increase in hematocrit. Clinicians may consider monitoring for erythrocytosis after starting and SGLT2i in kidney transplant recipients.

Subjects

MeSH terms (MEDLINE)

PolycythemiaKidney TransplantationThrombosisDiabetes Mellitus, Type 2HumansGlucoseSodiumTransplant Recipients

Author keywords

erythrocytosiskidney transplantsodium glucose contransport-2 receptor inhibitorsthrombosis

Substances

GlucoseSodium

Authors and institutions

  • University of British Columbia, Division of Nephrology, Kidney Transplant program, Vancouver, Canada.
  • University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, Canada.
  • Providence Healthcare, Seattle, USA.
  • Fraser Health, Surrey, Canada.
  • Providence Health Research Institute, Seattle, USA.

ORCID profiles: Marianna Leung, Catherine Cheung, Olwyn Johnston

Cite

APA

Gill, M., Leung, M., Luo, C. Y., Cheung, C., Beauchesne, A., Chang, D., Lan, J., & Johnston, O. (2023). Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor. Clinical Transplantation. https://doi.org/10.1111/ctr.15013

Vancouver

Gill M, Leung M, Luo CY, Cheung C, Beauchesne A, Chang D, et al. Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor. Clinical Transplantation. 2023. doi:10.1111/ctr.15013

BibTeX
@article{Gill2023,
  author = {Gill, Maia and Leung, Marianna and Luo, Cindy Y and Cheung, Catherine and Beauchesne, Arielle and Chang, Doris and Lan, James and Johnston, Olwyn},
  title = {Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.15013}
}
Start for free →